Postoperative Serum Cortisol and Cushing Disease Recurrence in Patients With Corticotroph Adenomas

Author:

Catalino Michael P123ORCID,Moore Dominic T4,Ironside Natasha5,Munoz Alexander R6,Coley Justin5,Jonas Rachel7,Kearns Kathryn5,Min Le8,Vance Mary Lee9,Jane John A5,Laws Edward R2

Affiliation:

1. Department of Neurosurgery, The University of North Carolina , Chapel Hill, NC 27599 , USA

2. Department of Neurosurgery, Brigham and Women's Hospital/Harvard Medical School , Boston, MA 02115 , USA

3. Department of Neurosurgery, Texas MD Anderson Cancer Center , Houston, TX 77030 , USA

4. Department of Biostatistics, Lineberger Comprehensive Cancer Center, University of North Carolina , Chapel Hill, NC 27599 , USA

5. Department of Neurosurgery, University of Virginia , Charlottesville, VA 22903 , USA

6. Harvard Medical School-MIT Health Sciences and Technology , Boston, MA 02115 , USA

7. Department of Otolaryngology, University of Virginia Health System , Charlottesville, VA 22903 , USA

8. Division of Endocrinology, Brigham and Women's Hospital/Harvard Medical School , Boston, MA 02115 , USA

9. Division of Endocrinology, University of Virginia Health System , Charlottesville, VA 22903 , USA

Abstract

Abstract Context In Cushing disease, the association between the rate of serum cortisol decline and recurrent disease after corticotroph adenoma removal has not been adequately characterized. Objective To analyze postoperative serum cortisol and recurrence rates in Cushing disease. Methods Patients with Cushing disease and pathology-confirmed corticotroph adenoma were retrospectively studied. Cortisol halving time was estimated using exponential decay modeling. Halving time, first postoperative cortisol, and nadir cortisol values were collected using immediate postoperative inpatient laboratory data. Recurrence and time-to-recurrence were estimated and compared among cortisol variables. Results A total of 320 patients met inclusion/exclusion criteria for final analysis, and 26 of those patients developed recurrent disease. Median follow-up time was 25 months (95% CI, 19-28 months), and 62 patients had ≥ 5 years follow-up time. Higher first postoperative cortisol and higher nadir were associated with increased risk of recurrence. Patients who had a first postoperative cortisol ≥ 50 µg/dL were 4.1 times more likely to recur than those with a first postoperative cortisol < 50 µg/dL (HR 4.1, 1.8-9.2; P = .0003). Halving time was not associated with recurrence (HR 1.7, 0.8-3.8, P = .18). Patients with a nadir cortisol ≥2 µg/dL were 6.6 times more likely to recur than those with a nadir cortisol of < 2 µg/dL (HR 6.6, 2.6-16.6, P < .0001). Conclusion Postoperative nadir serum cortisol is the most important cortisol variable associated with recurrence and time-to-recurrence. Compared to first postoperative cortisol and cortisol halving time, a nadir < 2 µg/dL showed the strongest association with long-term remission and typically occurs within the first 24 to 48 hours after surgery.

Publisher

The Endocrine Society

Subject

Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Reference42 articles.

1. Cushing's disease: pathobiology, diagnosis, and management;Lonser;J Neurosurg,2016

2. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism);Cushing;Bull Johns Hopkins Hosp,1932

3. Cushing's syndrome;Orth;N Engl J Med,1995

4. Cerebral atrophy in Cushing's disease;Simmons;Surg Neurol,2000

5. Overall and disease-specific mortality in patients with Cushing disease: a Swedish Nationwide Study;Ragnarsson;J Clin Endocrinol Metab,2019

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3